Gate one: the EHR decides who is a candidate
This is the part of healthcare tech lead generation with no equivalent in other verticals.
The KLAS US Acute Care EHR data for 2026 puts Epic at roughly 44% of acute care hospitals and around 57% of beds, with Oracle Health, formerly Cerner, at about 22% of hospitals and 20% of beds. Combined, those two control roughly two thirds of the US hospital market.
The trend matters as much as the share. Epic added 77 hospitals in 2025 while Oracle Health lost 56, and across 2021 to 2025 Epic recorded a net gain of 568 hospitals against Oracle Health's net loss of 173.
What that means for healthcare lead generation:
If your product needs to read or write clinical data and you have not integrated with Epic, you are not in the consideration set for the majority of large health systems and academic medical centers. Not disadvantaged. Not evaluated unfavorably. Absent.
The marketplace is a channel, not just a certification. Epic's app marketplace gives visibility to Epic customer IT decision-makers, which functions as a genuine sales channel for health tech companies. The Cerner Code developer program provides equivalent access on the Oracle Health side.
Worth being realistic about what a listing does and does not do. It creates visibility and it signals technical legitimacy. It does not guarantee adoption, and most health systems run their own vendor review independent of marketplace status. Treat it as clearing a prerequisite and opening a door, not as a lead generation engine.
Which one first? If you sell to large health systems and academic medical centers, Epic, regardless of the approval timeline. If you target mid-sized hospitals, federal health or mixed-vendor environments, Oracle Health is more likely and historically more open to third-party integration. For ambulatory and physician practices, athenahealth covers a genuinely different segment.
A timing signal worth watching. KLAS noted that overall EHR purchasing decisions fell roughly 40% from 2024, as health systems held capital for AI investment amid policy uncertainty. Budget did not disappear. It moved. A health tech product positioned against AI-era operational efficiency is competing for money that is actively being allocated, while one positioned as a core system replacement is competing for money that is being held.
Gate two: the reference decides who is credible
Healthcare technology buys by precedent. The first question in most evaluations is which comparable institutions already run this.
"Comparable" is narrower than vendors expect. A 400-bed community hospital does not consider an academic medical center a relevant reference. A payer does not consider a provider reference relevant. Bed count, teaching status, geography, EHR and patient population all filter.
The practical implications:
Build the reference list deliberately, segmented by institution type, and get written permission to name them. A logo you cannot name is worth very little in this market.
Your first three customers in a segment are worth more than their contract value, because they unlock the segment. Price and support them accordingly.
Peer-reviewed evidence and published outcomes data carry weight that marketing claims do not. A case study is marketing. A published study is evidence, and health system buyers know the difference.
Where no reference exists, a pilot at a recognizable institution substitutes, which is why pilots at named systems are worth running even at unattractive economics.
Gate three: the clinician decides who survives
A CIO or CMIO signs the contract. A nurse, physician or technician uses the product. Those are different people with different criteria and, frequently, no shared conversation.
The failure mode is specific and expensive. A deal closes on an executive business case, deploys, encounters clinician resistance because it adds clicks to a workflow already blamed for burnout, adoption stalls, and the renewal does not happen. From the vendor's side this reads as a churn problem. It was a lead generation problem, because the wrong stakeholder was engaged from the start.
What to do about it during healthcare lead generation, not after:
Produce material for clinicians that is not a sales asset. Workflow documentation, time-to-complete comparisons, honest accounting of what the product adds to a shift.
Ask who will use this in the first discovery conversation, and ask whether they have seen it.
Treat a clinical champion as equal in value to an executive champion. The executive gets the deal signed. The clinician gets it renewed.
Who actually buys healthcare technology
| Role |
Cares about |
Blocks over |
| CIO |
Integration burden, security posture, portfolio fit |
Another system to maintain, EHR conflict |
| CMIO or CNIO |
Clinical workflow impact, adoption risk |
Anything that adds clicks or alerts |
| CFO or VP Finance |
Reimbursement impact, cost, capital versus operating expense |
A business case that cannot be defended |
| Chief Compliance or Privacy Officer |
PHI handling, BAA terms, audit trail |
An unanswered question about data |
| Department or service line leader |
Whether it solves their specific problem |
Being handed a tool chosen elsewhere |
| Supply chain or procurement |
Contract vehicle, GPO alignment, terms |
Non-standard contracting, no GPO agreement |
| The end clinician |
Whether it makes their shift easier or harder |
Quietly, by not using it |
Seven functions, and the one at the bottom has no formal authority and the most practical power. Building qualification criteria that account for all of them is what separates a real healthcare tech lead from a contact record.
Group purchasing organizations and integrated delivery networks add another layer. A GPO agreement can shortcut procurement considerably, and its absence can block a deal that every stakeholder wanted.
12 healthcare lead generation strategies
1. Integrate before you market
If you need clinical data and lack an EHR integration, integration is your lead generation priority, not a roadmap item. Everything else in your healthcare tech lead generation program underperforms until it exists.
2. Publish your security posture before anyone asks
HIPAA is baseline. HITRUST certification, SOC 2 Type II, a signed BAA template, a data flow diagram and a completed security questionnaire are what actually move a health system's vendor review. Put them where a buyer can find them without a conversation. This is the same principle behind winning technical buyers who evaluate before they talk to anyone.
3. Map your product to a reimbursement or regulatory driver
Healthcare budget follows mandates and reimbursement. Information blocking rules under the 21st Century Cures Act, TEFCA participation, quality measure reporting, and payer requirements all create dated, non-optional spending. That is more concrete than any efficiency claim.
4. Build the peer reference program before you need it
Segmented by institution type, with named permission. This is the highest-return non-product investment in health tech, and it compounds.
5. Go to HIMSS and ViVE with a meeting calendar
Healthcare runs on a small number of large conferences where the entire buying committee attends. A booth hoping for traffic underperforms a calendar of pre-booked meetings badly, and routing those bookings to the right rep's calendar is what makes it work at scale. Our event pipeline guide covers the mechanics, and the event pipeline playbook covers the setup.
6. Write for clinicians, not only for executives
Two audiences, two sets of material. The clinician content should be genuinely useful whether or not they buy, and it should not read as marketing. Pricing transparency helps here too, since a published price filters institutions that could never fund it.
7. Publish outcomes, not claims
A study, a measured result at a named institution, or a peer-reviewed publication. In a market trained on evidence hierarchies, unsupported claims are discounted automatically.
8. Use the EHR marketplace as a discovery channel
A marketplace listing puts you in front of IT decision-makers who are actively looking for solutions compatible with their stack. Treat it as a channel with its own conversion path rather than a badge.
9. Target by EHR, not only by bed count
An account's EHR tells you more about whether you can serve them than their size does. Segment your target list by EHR first, and identify which of those systems are already visiting your site.
10. Run ABM on named health systems
The market is finite and nameable. There are a few thousand US hospitals and a few hundred systems that matter for most products. Account-based marketing fits this better than volume demand generation, and the account view is where target system engagement becomes visible.
11. Design pilots to convert, not just to prove
A pilot with no defined path to enterprise rollout becomes a permanent pilot. Scope the success criteria, the decision date, and who signs the expansion before it starts.
12. Watch for the signals that matter here
New CIO or CMIO, EHR migration announcement, merger or acquisition, a publicly reported incident, a new quality mandate, or a large capital announcement. These are buyer intent signals specific to this market, and turning them into pipeline is a different job from generating them.
HIPAA and your marketing
Worth being precise, because this is where health tech marketing teams either over-restrict or create real exposure.
HIPAA governs protected health information. Marketing to a hospital's CIO about your product is not PHI handling. Marketing that touches patient data is.
Where it actually bites in lead generation:
Demos using real patient data require a BAA and usually a de-identified environment instead. Case studies naming outcomes need permission and often de-identification. Any tool in your marketing stack that could touch PHI, including chat, forms and analytics, needs review. Email marketing to providers is generally fine; email marketing that references a patient relationship is not.
What this does not prohibit: normal B2B demand generation, content marketing, conference presence, outbound to named institutional contacts, or retargeting business audiences.
The common error is treating HIPAA as a reason to avoid modern lead generation entirely. The correct posture is a documented review of which systems could touch PHI, and normal practice everywhere else.
Where healthcare tech pipeline actually comes from
| Source |
Why it works here |
Time to first leads |
| EHR marketplace listings |
Puts you in front of IT decision-makers screening for stack compatibility |
1 to 2 quarters after approval |
| Named peer references |
The first question in most evaluations |
Compounds from customer one |
| HIMSS, ViVE and specialty conferences |
The whole committee attends one of a few events |
Days after the event |
| Clinical and professional associations |
Credibility with the people who decide adoption |
2 to 4 quarters |
| GPO and IDN contract vehicles |
Removes a procurement barrier |
2 to 4 quarters |
| Published outcomes and research |
Evidence outperforms claims in this market |
Slow, durable |
| Analyst coverage, particularly KLAS |
Health systems consult it during shortlisting |
2 to 4 quarters |
| Consultant and advisory relationships |
Advisors shape shortlists before vendors are contacted |
Ongoing |
| Search and technical content |
Reaches the researcher, not the decider |
4 to 9 months |
| Outbound to named systems |
Works on a researched list, fails at volume |
Weeks |
Two of those deserve emphasis because they appear in almost no general B2B advice. KLAS ratings function as an analyst gate specific to healthcare, and health systems genuinely consult them. Consultants and advisory firms frequently build the shortlist before any vendor is contacted, which means the evaluation you are trying to enter has often already happened.
How to measure healthcare tech lead generation
| Do not rely on |
Measure instead |
| Lead volume |
Named target systems with multi-person engagement |
| Standard lead decay assumptions |
Accounts re-engaging after 6 to 12 months of silence |
| Blended sales cycle |
Cycle by segment, and time in each gate |
| MQL to SQL |
Progression through EHR fit, security review and clinical validation |
| Campaign attribution |
Whether a reference, a conference or an advisor was involved in closed-won |
| Win rate against competitors |
Win rate against no decision and against internal build |
The measurement most health tech teams lack: what share of your lost deals failed at the EHR integration gate, the security review, or clinician adoption. Those three have completely different fixes, and none of them is more healthcare tech leads.
On timing, a lead that goes quiet for two quarters is normal here rather than dead. Purging the CRM on standard decay rules discards accounts that are in budget planning, which is funnel leakage disguised as hygiene.
How Knock AI helps convert healthcare tech leads
The gates above are not conversion problems, and nothing in a conversion layer addresses EHR integration or clinical validation. What it does address is the part in between.
Seeing which health systems are engaging. Knock Reveal identifies anonymous visitors at organization level, which in a market of a few hundred nameable target systems turns your website into an account monitor.
Scoring at the account level. Knock Intent reads engagement across an account rather than per contact, which matters when a seven-person committee researches separately over months.
Conversation instead of a form. Knock Chat lets a CMIO or IT director start a conversation without submitting a form, which is what removing the form at high-intent moments is for.
Routing that respects ownership. Knock Routing and lead routing send a recognized health system to the rep who owns it, and response time matters during the narrow windows when a committee is actively evaluating.
What it does not do: build your Epic integration, secure your HITRUST certification, produce your peer references, or win over your clinical users. Those decide whether you have a market. This decides whether you lose the demand you already created.
Healthcare tech lead generation FAQs
What is healthcare tech lead generation?
Healthcare tech lead generation is the process of identifying, engaging and converting healthcare organizations into qualified sales opportunities for a health technology product. Healthcare lead generation differs from standard B2B because EHR integration, peer references and clinical acceptance gate the purchase independently of marketing activity.
Why is healthcare lead generation so difficult?
Three gates sit outside marketing's control. The EHR determines whether you are technically a candidate, peer references determine whether you are credible, and clinicians determine whether the product survives deployment. Add 12 to 24 month cycles and buying committees of six or more, and demand generation alone does not produce pipeline.
How long is the healthcare technology sales cycle?
Commonly 12 to 24 months for enterprise health system deals, shorter for departmental purchases and ambulatory practices. Budget cycles, committee calendars and security review set the pace more than buyer enthusiasm does.
Do you need Epic integration to sell to hospitals?
If your product reads or writes clinical data and you target large health systems or academic medical centers, effectively yes. Epic holds roughly 44% of US acute care hospitals and around 57% of beds. Without integration you are frequently not in the consideration set at all rather than being evaluated unfavorably.
Is an EHR marketplace listing worth it?
It clears a prerequisite and gives visibility to IT decision-makers actively screening for stack-compatible solutions, which makes it a genuine channel. It does not guarantee adoption, and most health systems run their own vendor review independent of marketplace status.
Who makes the buying decision for healthcare technology?
Typically a committee spanning CIO, CMIO or CNIO, finance, compliance, the department leader, and procurement. The end clinician usually has no formal authority and the most practical power, because adoption failure undoes the purchase.
How does HIPAA affect healthcare marketing?
It governs protected health information, not ordinary B2B marketing to institutional buyers. Where it bites is demos using real patient data, case studies naming outcomes, and any marketing tool that could touch PHI. Standard demand generation to hospital executives is not restricted by HIPAA.
What is the average cost per lead in healthcare tech?
Published figures vary too widely to be useful, because deal sizes range from departmental purchases to eight-figure enterprise agreements. Calculate cost per qualified opportunity against your own segment rather than borrowing a benchmark.
How do you get healthcare references when you have no customers?
Run pilots at recognizable institutions even at unattractive economics, because the first three customers in a segment unlock the segment. Published outcomes data and peer-reviewed evidence substitute partially where no reference exists.
What triggers a healthcare technology purchase?
A new CIO or CMIO, an EHR migration, a merger, a reported incident, a new quality or regulatory mandate, or a capital allocation announcement. Regulatory deadlines are the most reliable, because the budget is not optional and the date is published.
Should healthcare tech companies use ABM?
Usually yes. The market is finite and nameable, a few thousand US hospitals and a few hundred systems that matter for most products. That suits account-based targeting far better than volume demand generation.
Why do healthcare tech deals fail after closing?
Most often clinician rejection. The deal was built on an executive business case, the product added friction to a clinical workflow, adoption stalled and the renewal did not happen. That is a lead generation failure, because the wrong stakeholder was engaged from the beginning.
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
